REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.
A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
Integration Simplifies ICHRA Administration Through HR and Payroll Data SyncINDIANAPOLIS, Jan. 13, 2026 /PRNewswire/ --…
Recognition underscores Brillio's AI-driven innovation and measurable impact on health outcomes, cost, patient experience, and…
Healthcare Technology Leader Received Top Recognition for Innovative Approachto Remote Care for Chronic Disease ManagementSEATTLE,…
PITTSBURGH, Jan. 13, 2026 /PRNewswire/ -- "I wanted to create a simple and easy way…
Tenth annual awards evaluate 24 leading health insurers across 120+ digital attributes spanning desktop and…
More than 100 new and expanded LifeSphere customers, 34 global go-lives, and rapid enterprise adoption…